Malignant Exocrine Pancreas Neoplasm — Trials

Malignant Exocrine Pancreas Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 360
Recruiting: 209
Ph III recruiting: 23
Growth YoY: +39.4%
Industry share: 40%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (136)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04005690	Targeted Pathway Inhibition in Patients With Pancreatic Cancer	recruiting	Early Phase 1	90	OHSU Knight Cancer InstituteOTHER	1	Sep 4, 2026	clinicaltrials
NCT06122896	Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals	recruiting	Early Phase 1	5,000	Dana-Farber Cancer InstituteOTHER	1	May 29, 2026	clinicaltrials